Published in Adv Drug Deliv Rev on May 07, 2004
Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine (2008) 4.59
Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed (2007) 2.12
Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol (2010) 1.89
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med (2005) 1.63
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine (2007) 1.41
Drug transport to brain with targeted nanoparticles. NeuroRx (2005) 1.37
Drug delivery systems: An updated review. Int J Pharm Investig (2012) 1.31
Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics (2014) 1.29
Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles. Int J Nanomedicine (2007) 1.21
Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech (2010) 1.16
Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther (2009) 1.05
Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech (2009) 1.00
Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. AAPS PharmSciTech (2008) 1.00
Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomedicine (2013) 1.00
In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano (2011) 0.99
Formulation and targeting efficiency of Cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci (2010) 0.97
New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell. Int J Nanomedicine (2011) 0.94
Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine (2007) 0.91
Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech (2010) 0.91
Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine (2013) 0.90
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery. J Drug Deliv (2011) 0.90
A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett (2012) 0.89
Delivery of cancer therapeutics using nanotechnology. Pharmaceutics (2013) 0.88
Effect of poly-α, γ, L-glutamic acid as a capping agent on morphology and oxidative stress-dependent toxicity of silver nanoparticles. Int J Nanomedicine (2011) 0.86
Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Int J Nanomedicine (2012) 0.85
Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J Ocul Pharmacol Ther (2013) 0.85
Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design. Res Pharm Sci (2015) 0.85
Nanotechnology and the treatment of HIV infection. Viruses (2012) 0.84
Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine (2014) 0.84
Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev (2009) 0.84
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
Immune cell recruitment and cell-based system for cancer therapy. Pharm Res (2007) 0.83
pH-sensitive poly(lactide-co-glycolide) nanoparticle composite microcapsules for oral delivery of insulin. Int J Nanomedicine (2015) 0.81
Nanocarriers for vascular delivery of anti-inflammatory agents. Annu Rev Pharmacol Toxicol (2014) 0.81
Nanoemulsion-based delivery systems for poorly water-soluble bioactive compounds: Influence of formulation parameters on Polymethoxyflavone crystallization. Food Hydrocoll (2011) 0.81
Organized polysaccharide fibers as stable drug carriers. Carbohydr Polym (2013) 0.81
Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol (2008) 0.81
Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel. Saudi Pharm J (2013) 0.81
Multi criteria decision making to select the best method for the preparation of solid lipid nanoparticles of rasagiline mesylate using analytic hierarchy process. J Adv Pharm Technol Res (2014) 0.80
Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev (2015) 0.80
Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int J Nanomedicine (2012) 0.80
Nanotechnology applications for the therapy of liver fibrosis. World J Gastroenterol (2014) 0.80
Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. Int J Nanomedicine (2014) 0.80
Coating Solid Lipid Nanoparticles with Hyaluronic Acid Enhances Antitumor Activity against Melanoma Stem-like Cells. Theranostics (2015) 0.78
Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway. Int J Nanomedicine (2014) 0.78
A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules. Arch Biochem Biophys (2016) 0.77
Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice. J Nanobiotechnology (2013) 0.77
Formulation Strategy for the Delivery of Cyclosporine A: Comparison of Two Polymeric Nanospheres. Sci Rep (2015) 0.77
Nanocarriers and nanoparticles for skin care and dermatological treatments. Indian Dermatol Online J (2013) 0.77
Preparation and characterization of catalase-loaded solid lipid nanoparticles protecting enzyme against proteolysis. Int J Mol Sci (2011) 0.77
Solid Lipid Nanoparticles of Atovaquone Based on 2(4) Full-Factorial Design. Iran J Pharm Res (2015) 0.77
Comparative study on the suitability of two techniques for measuring the transfer of lipophilic drug models from lipid nanoparticles to lipophilic acceptors. AAPS PharmSciTech (2014) 0.77
Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine. Acta Pharmacol Sin (2013) 0.77
Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes. Int J Nanomedicine (2014) 0.77
Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection. Int J Nanomedicine (2015) 0.77
Novel lutein loaded lipid nanoparticles on porcine corneal distribution. J Ophthalmol (2014) 0.76
Alendronate Sodium as Enteric Coated Solid Lipid Nanoparticles; Preparation, Optimization, and In Vivo Evaluation to Enhance Its Oral Bioavailability. PLoS One (2016) 0.76
Solid lipid nanoparticle-based calix[n]arenes and calix-resorcinarenes as building blocks: synthesis, formulation and characterization. Int J Mol Sci (2013) 0.76
Preparation of SLN-containing Thermoresponsive In-situ Forming Gel as a Controlled Nanoparticle Delivery System and Investigating its Rheological, Thermal and Erosion Behavior. Iran J Pharm Res (2015) 0.75
Solid lipid nanoparticles loaded with iron to overcome barriers for treatment of iron deficiency anemia. Drug Des Devel Ther (2015) 0.75
Characterization and in vivo evaluation of novel lipid-chlorambucil nanospheres prepared using a mixture of emulsifiers for parenteral administration. Int J Nanomedicine (2010) 0.75
The Effect of Millisecond Pulsed Electric Fields (msPEF) on Intracellular Drug Transport with Negatively Charged Large Nanocarriers Made of Solid Lipid Nanoparticles (SLN): In Vitro Study. J Membr Biol (2016) 0.75
Development of a large peptoid-DOTA combinatorial library. Biopolymers (2016) 0.75
Development of solid lipid nanoparticles containing total flavonoid extract from Dracocephalum moldavica L. and their therapeutic effect against myocardial ischemia-reperfusion injury in rats. Int J Nanomedicine (2017) 0.75
MAS (1)H NMR Probes Freezing Point Depression of Water and Liquid-Gel Phase Transitions in Liposomes. Biophys J (2016) 0.75
Carrier-based drug delivery system for treatment of acne. ScientificWorldJournal (2014) 0.75
Pharmacokinetic and anti-inflammatory effects of sanguinarine solid lipid nanoparticles. Inflammation (2014) 0.75
Miconazole-loaded solid lipid nanoparticles: formulation and evaluation of a novel formula with high bioavailability and antifungal activity. Int J Nanomedicine (2016) 0.75
Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomedicine (2017) 0.75
Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Int J Nanomedicine (2016) 0.75
Treating Cancer by Targeting Telomeres and Telomerase. Antioxidants (Basel) (2017) 0.75
Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems. Kona (2016) 0.75
Effect of the moist-heat sterilization on fabricated nanoscale solid lipid particles containing rasagiline mesylate. Int J Pharm Investig (2015) 0.75
Nanotechnology-Based Approach in Tuberculosis Treatment. Tuberc Res Treat (2017) 0.75
Increased therapeutic efficacy of a newly synthesized tyrosinase inhibitor by solid lipid nanoparticles in the topical treatment of hyperpigmentation. Drug Des Devel Ther (2016) 0.75
A Hybrid Nanomaterial for the Controlled Generation of Free Radicals and Oxidative Destruction of Hypoxic Cancer Cells. Angew Chem Int Ed Engl (2017) 0.75
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev (2001) 3.07
Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm (2000) 1.73
Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res (1998) 1.51
Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm (1999) 1.42
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm (2004) 1.37
Amphotericin B. Appl Microbiol Biotechnol (2005) 1.28
Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis (1993) 1.27
Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release (2002) 1.17
Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials (1999) 1.16
Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm (2000) 1.05
Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm (2001) 1.02
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother (2000) 1.01
In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J Gene Med (2000) 1.01
Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci (2008) 1.01
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother (2001) 0.99
Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm (2005) 0.99
Nanosuspensions of poorly soluble drugs--reproducibility of small scale production. Int J Pharm (2000) 0.98
Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int J Pharm (2000) 0.97
Beta-carotene-loaded nanostructured lipid carriers. J Food Sci (2008) 0.96
Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition. J Control Release (1998) 0.96
Solid lipid nanoparticles (SLN)--a novel carrier for UV blockers. Pharmazie (2001) 0.95
Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm (2011) 0.95
A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. Int J Cosmet Sci (2001) 0.94
Solid lipid nanoparticles (SLN/Lipopearls)--a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul (2000) 0.93
Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm (2001) 0.93
Influence of different parameters on reconstitution of lyophilized SLN. Int J Pharm (2000) 0.92
Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul (2006) 0.91
Adsorption kinetics of plasma proteins on ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles. Int J Pharm (2012) 0.90
SLN and NLC for topical delivery of ketoconazole. J Microencapsul (2005) 0.90
Protein rejecting properties of PEG-grafted nanoparticles: influence of PEG-chain length and surface density evaluated by two-dimensional electrophoresis and bicinchoninic acid (BCA)-proteinassay. Pharmazie (2006) 0.90
The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. Life Sci (1987) 0.89
Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm (2002) 0.89
Antimicrobial, antitumor and antileishmania screening of medicinal plants from Guinea-Bissau. Phytomedicine (1999) 0.89
Formulation of intravenous carbamazepine emulsions by SolEmuls technology. Eur J Pharm Biopharm (2003) 0.89
Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: analysing the role of proteins and glycoproteins. J Gene Med (2003) 0.89
Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release (2001) 0.89
Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. Int J Pharm (2001) 0.88
Identification of plasma proteins facilitated by enrichment on particulate surfaces: analysis by two-dimensional electrophoresis and N-terminal microsequencing. Electrophoresis (1997) 0.87
Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake. Clin Nutr (1992) 0.87
Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J Microencapsul (1999) 0.87
The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents. Pharmazie (2006) 0.86
Determination of plasma protein adsorption on magnetic iron oxides: sample preparation. Pharm Res (1997) 0.86
New trichothecenes isolated from Holarrhena floribunda. J Nat Prod (2000) 0.86
Nanostructured lipid carriers as novel carrier for sunscreen formulations. Int J Cosmet Sci (2007) 0.85
Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials (1987) 0.85
Liquid and semisolid SLN dispersions for topical application: rheological characterization. Eur J Pharm Biopharm (2004) 0.85
Preliminary evidence for a mitochondrion in Cryptosporidium parvum: phylogenetic and therapeutic implications. J Eukaryot Microbiol (1999) 0.84
Two-time window and multiangle photon correlation spectroscopy size and zeta potential analysis--highly sensitive rapid assay for dispersion stability. J Pharm Sci (2000) 0.84
Antileishmanial activity of hydrolyzable tannins and their modulatory effects on nitric oxide and tumour necrosis factor-alpha release in macrophages in vitro. Planta Med (2001) 0.84
Skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) incorporated into hydrogel. Pharmazie (2005) 0.84
Structure-cytotoxicity relationships of a series of natural and semi-synthetic simple coumarins as assessed in two human tumour cell lines. Z Naturforsch C (1997) 0.84
Comparison of protein adsorption patterns onto differently charged hydrophilic superparamagnetic iron oxide particles obtained in vitro and ex vivo. Electrophoresis (2001) 0.84
Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul (2006) 0.84
Production & stability of stavudine solid lipid nanoparticles--from lab to industrial scale. Int J Pharm (2010) 0.83
Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm (1999) 0.83
Jet nebulization of PEI/DNA polyplexes: physical stability and in vitro gene delivery efficiency. J Gene Med (2002) 0.83
Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm (2001) 0.83
Adsorption kinetics of plasma proteins on oil-in-water emulsions for parenteral nutrition. Eur J Pharm Biopharm (2000) 0.82
Semisolid SLN dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. Eur J Pharm Biopharm (2002) 0.82
Solid lipid nanoparticles (SLN)--effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie (2006) 0.82
Skin photoprotection improvement: synergistic interaction between lipid nanoparticles and organic UV filters. Int J Pharm (2011) 0.81
Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm (2001) 0.81
Resveratrol nanosuspensions for dermal application--production, characterization, and physical stability. Pharmazie (2009) 0.81
Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1H NMR. Pharmazie (2005) 0.81
Pneumocystis carinii synthesizes four ubiquinone homologs: inhibition by atovaquone and bupravaquone but not by stigmatellin. J Eukaryot Microbiol (2001) 0.81
The influence of the sample preparation on plasma protein adsorption patterns on polysaccharide-stabilized iron oxide particles and N-terminal microsequencing of unknown proteins. J Drug Target (1997) 0.81
Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J Pharm Biopharm (2004) 0.81
The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with solutol HS 15. Eur J Pharm Biopharm (2000) 0.80
Expression of the 2,4-D degradative pathway of pJP4 in an alkaliphilic, moderately halophilic soda lake isolate, Halomonas sp. EF43. Extremophiles (2001) 0.80
Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Pharmazie (2004) 0.80
A novel approach based on lipid nanoparticles (SLN) for topical delivery of alpha-lipoic acid. J Microencapsul (2005) 0.80
Enhancement of antimicrobial activity of tannins and related compounds by immune modulatory effects. Basic Life Sci (1999) 0.80
Analysis of plasma protein adsorption onto polystyrene particles by two-dimensional electrophoresis: comparison of sample application and isoelectric focusing techniques. Electrophoresis (2000) 0.80
Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul (2001) 0.79
SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs. Pharm Dev Technol (2007) 0.79
Modified Rose Bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN). Eur J Pharm Sci (2012) 0.79
Rheology of nanostructured lipid carriers (NLC) suspended in a viscoelastic medium. Pharmazie (2005) 0.79
smartCrystal combination technology--scale up from lab to pilot scale and long term stability. Pharmazie (2010) 0.79
Inhibition of mutagenesis of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) by coumarins and furanocoumarins, chromanones and furanochromanones. Mutat Res (1995) 0.79
Tannins and related compounds: killing of amastigotes of Leishmania donovani and release of nitric oxide and tumour necrosis factor alpha in macrophages in vitro. Z Naturforsch C (2001) 0.79
Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm (2011) 0.78
Physical and chemical stability of nanostructured lipid drug carriers (NLC) based on natural lipids from Baikal region (Siberia, Russia). Pharmazie (2011) 0.78
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for application of ascorbyl palmitate. Pharmazie (2005) 0.78
Etherolytic cleavage of 4-(2,4-dichlorophenoxy)butyric acid and 4-(4-chloro-2-methylphenoxy)butyric acid by species of Rhodococcus and Aureobacterium isolated from an alkaline environment. J Basic Microbiol (1998) 0.78
3-Hexulose-6-phosphate synthase from Acetobacter methanolicus MB58. Methods Enzymol (1990) 0.78
Surface-modified amikacin-liposomes: organ distribution and interaction with plasma proteins. J Drug Target (1998) 0.78
Preparation and characterization of quercetin nanocrystals. J Pharm Sci (2010) 0.78
Development of lycopene-loaded nanostructured lipid carriers: effect of rice oil and cholesterol. Pharmazie (2013) 0.78
Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. J Microencapsul (2001) 0.78
The influence of the sample preparation on plasma protein adsorption patterns on polysaccharide-stabilized iron oxide particles and N-terminal microsequencing of unknown proteins. J Drug Target (1998) 0.78
Evaluation of the antimicrobial potency of tannins and related compounds using the microdilution broth method. Planta Med (1999) 0.78
Nanosuspensions of hesperetin: preparation and characterization. Pharmazie (2014) 0.77
Interactions of nanoparticles with body proteins--improvement of 2D-PAGE-analysis by internal standard. Int J Pharm (2000) 0.77
Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int J Pharm (2000) 0.77
The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int J Pharm (2001) 0.77